Literature DB >> 22300751

Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas.

Gian Kayser1, Luzie Schulte-Uentrop, Wulf Sienel, Martin Werner, Paul Fisch, Bernward Passlick, Axel Zur Hausen, Christian Stremmel.   

Abstract

Within the concert of immune reactions against tumour cells cytotoxic and regulatory T-cells are of utmost importance. Several studies revealed contradictory results on this issue. We therefore focused on functional expression patterns and localization of tumour-infiltrating T-lymphocytes in non-small cell lung cancer (NSCLC) and their impact on patient's survival. 232 curatively operated NSCLC patients were included. After histological reevaluation and construction of tissue-multi-arrays immunohistochemical doublestains for CD3/CD8 and CD4/CD25 were performed to evaluate the total number of T-cells and their subsets of cytotoxic and activated T-cells. Additionally, the localization of the lymphocytes was included in the analysis. Hereby, T-cells within the tumour stroma were regarded as stromal, those among cancer cells as intraepithelial. The number of lymphocytes differed significantly between the histological subtypes being most prominent in large cell carcinomas. Survival analysis showed that high numbers of stromal T-lymphocytes are of beneficial prognostic influence in NSCLC patients. This also proved to be an independent prognostic factor in adenocarcinomas. Thus, in a large and well characterized cohort of NSCLC this is the first study to determine the prognostic value of stromal T-lymphocytes, as these are an independent prognosticator in NSCLC especially in adenocarcinomas whereas intraepithelial T-cells are not.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300751     DOI: 10.1016/j.lungcan.2012.01.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  22 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].

Authors:  G Kayser
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

3.  Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies.

Authors:  Joseph M Obeid; Nolan A Wages; Yinin Hu; Donna H Deacon; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-10-21       Impact factor: 6.968

4.  Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor.

Authors:  Marc-Antoine Allard; Jean Baptiste Bachet; Alain Beauchet; Catherine Julie; Robert Malafosse; Christophe Penna; Bernard Nordlinger; Jean-François Emile
Journal:  Diagn Pathol       Date:  2012-11-13       Impact factor: 2.644

5.  Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy.

Authors:  Zheng-Hao Ye; Hao Long; Ze-Rui Zhao
Journal:  J Immunol Res       Date:  2022-04-28       Impact factor: 4.493

6.  Downregulation of MTSS1 expression is an independent prognosticator in squamous cell carcinoma of the lung.

Authors:  G Kayser; A Csanadi; S Kakanou; A Prasse; A Kassem; E Stickeler; B Passlick; A Zur Hausen
Journal:  Br J Cancer       Date:  2015-01-27       Impact factor: 7.640

7.  Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer.

Authors:  Dong-Qiang Zeng; Yun-Fang Yu; Qi-Yun Ou; Xiao-Yin Li; Ru-Zhi Zhong; Chuan-Miao Xie; Qiu-Gen Hu
Journal:  Oncotarget       Date:  2016-03-22

Review 8.  Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis.

Authors:  Sha Zhao; Tao Jiang; Limin Zhang; Hui Yang; Xiaozhen Liu; Yijun Jia; Caicun Zhou
Journal:  Oncotarget       Date:  2016-06-14

Review 9.  Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.

Authors:  Marlies E Heuvers; Joachim G Aerts; Robin Cornelissen; Harry Groen; Henk C Hoogsteden; Joost P Hegmans
Journal:  BMC Cancer       Date:  2012-12-05       Impact factor: 4.430

10.  The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays.

Authors:  Nilanjana Tewari; Abed M Zaitoun; Arvind Arora; Srinivasan Madhusudan; Mohammad Ilyas; Dileep N Lobo
Journal:  BMC Cancer       Date:  2013-09-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.